Office of the Chief Scientist

Venture Capital Active Jerusalem, Israel Est. 1965
Last updated 2026-07-20
Portfolio
6
in our dataset
Rounds participated
7
Rounds led
6
Rounds' value
$12.5M
total disclosed, rounds participated
Stages
—

About

The 'Office of the Chief Scientist' (OCS) is a designation for several governmental units within various Israeli ministries, rather than a single startup or company. The most prominent historical OCS, which focused on industrial R&D, was established in 1965 and rebranded as the Israel Innovation Authority (IIA) in 2016. Other ministries, such as the Ministry of Innovation, Science and Technology, Ministry of Energy and Infrastructure, Ministry of Agriculture and Food Security, Ministry of Health, and Ministry of National Security, also have Chief Scientist offices that lead scientific activities and promote R&D in their respective fields.

Portfolio · 6

Nurami Medical
A biotechnology-driven company advancing innovation in soft-tissue repair, leveraging nanofibers and engineered biomaterials to transform patient recovery.
Led ★ 2 rounds $6.8M committed Latest: 2020-11
Facetrom
Pioneering technology that predicts the financial risk of a potential customer requesting a loan using facial analysis.
Led ★ 1 round $3.3M committed Latest: 2015-06
BrainStorm
A biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases.
Led ★ 1 round $800K committed Latest: 2013-12
Forconti Medical
Forconti Medical develops and produces disposable medical devices for Fecal Incontinence treatment.
Led ★ 1 round $675K committed Latest: 2011-05
Greenkote Plc.
A thermal diffusion metal coating company offering eco-friendly, corrosion-blocking solutions.
Led ★ 1 round $351K committed Latest: 2007-03
Distek Ltd.
Developer of thermal-diffusion zinc-coating technology for anti-corrosion protection of steel parts.
Led ★ 1 round $540K committed Latest: 2004-02

Investment activity

6 portfolio exits on record.

Portfolio by sector

Health Tech & Life Sciences28
Industrial Technologies7
Cyber Security6
Agriculture & Food Technologies5
Undisclosed4
Energy Tech4
Business Software3
Automotive & Mobility Technologies2

Q&A

What is the most recent exit for Office of the Chief Scientist?
The most recent exit for Office of the Chief Scientist was the acquisition of BELKIN Vision by Alcon Pharmaceuticals in July 2024 for $81M.
What is the primary sector focus for Office of the Chief Scientist's investments?
Office of the Chief Scientist primarily focuses its investments in Health Tech & Life Sciences, with 28 portfolio companies in this sector.
Can you name some notable portfolio companies in the Health Tech & Life Sciences sector?
Notable portfolio companies in the Health Tech & Life Sciences sector include BELKIN Vision, which was acquired for $81M, and TytoCare, which has raised $203.6M.
What is the typical investment stage for Office of the Chief Scientist?
Office of the Chief Scientist predominantly invests in Seed stage companies, with 54 Seed rounds recorded.
Which portfolio company has raised the most capital?
TytoCare has raised the most capital among the portfolio companies, with $203.6M in its E round.
Has Office of the Chief Scientist had any exits in the Cyber Security sector?
Yes, Office of the Chief Scientist has had three exits in the Cyber Security sector, including the acquisition of Fieldbit in November 2021 and CyKick Labs in July 2018.
What is the investment range for Office of the Chief Scientist?
The investment range for Office of the Chief Scientist is between $160K and $8M.
What was the acquisition value for BELKIN Vision?
BELKIN Vision was acquired for $81M by Alcon Pharmaceuticals in July 2024.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)